Abstract
As we move into the era of individualized cancer treatment, the need for more sophisticated cancer diagnostics has emerged. Cell-free (cf) nucleic acids (cf-DNA, cf-RNA) and other cellular nanoparticulates are now considered important and selective biomarkers. There is great hope that blood-borne cf-nucleic acids can be used for liquid biopsies, replacing more invasive tissue biopsies to analyze cancer mutations and monitor therapy. Conventional techniques for cf-nucleic acid biomarker isolation from blood are generally time-consuming, complicated and expensive. They require relatively large blood samples, which must be processed to serum or plasma before isolation of biomarkers can proceed. Such cumbersome sample preparation also limits the widespread use of powerful, downstream genomic analyses, including PCR and DNA sequencing. These limitations also preclude rapid, point-of-care diagnostic applications. Thus, new technologies that allow rapid isolation of biomarkers directly from blood will permit seamless sample-to-answer solutions that enable next-generation point-of-care molecular diagnostics.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1187-1200 |
| Number of pages | 14 |
| Journal | Expert Review of Molecular Diagnostics |
| Volume | 15 |
| Issue number | 9 |
| DOIs | |
| State | Published - Jan 1 2015 |
| Externally published | Yes |
Fingerprint
Keywords
- biomarkers
- cancer
- cell-free DNA
- cell-free RNA
- exosomes
- liquid biopsy
- molecular diagnostics
- nanoparticulates
- point-of-care
- sample preparation
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Molecular Medicine
- Molecular Biology
- Genetics
Cite this
Detecting cancer biomarkers in blood : Challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids. / Lewis, Jean M.; Heineck, Daniel P.; Heller, Michael (Mike).
In: Expert Review of Molecular Diagnostics, Vol. 15, No. 9, 01.01.2015, p. 1187-1200.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Detecting cancer biomarkers in blood
T2 - Challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids
AU - Lewis, Jean M.
AU - Heineck, Daniel P.
AU - Heller, Michael (Mike)
PY - 2015/1/1
Y1 - 2015/1/1
N2 - As we move into the era of individualized cancer treatment, the need for more sophisticated cancer diagnostics has emerged. Cell-free (cf) nucleic acids (cf-DNA, cf-RNA) and other cellular nanoparticulates are now considered important and selective biomarkers. There is great hope that blood-borne cf-nucleic acids can be used for liquid biopsies, replacing more invasive tissue biopsies to analyze cancer mutations and monitor therapy. Conventional techniques for cf-nucleic acid biomarker isolation from blood are generally time-consuming, complicated and expensive. They require relatively large blood samples, which must be processed to serum or plasma before isolation of biomarkers can proceed. Such cumbersome sample preparation also limits the widespread use of powerful, downstream genomic analyses, including PCR and DNA sequencing. These limitations also preclude rapid, point-of-care diagnostic applications. Thus, new technologies that allow rapid isolation of biomarkers directly from blood will permit seamless sample-to-answer solutions that enable next-generation point-of-care molecular diagnostics.
AB - As we move into the era of individualized cancer treatment, the need for more sophisticated cancer diagnostics has emerged. Cell-free (cf) nucleic acids (cf-DNA, cf-RNA) and other cellular nanoparticulates are now considered important and selective biomarkers. There is great hope that blood-borne cf-nucleic acids can be used for liquid biopsies, replacing more invasive tissue biopsies to analyze cancer mutations and monitor therapy. Conventional techniques for cf-nucleic acid biomarker isolation from blood are generally time-consuming, complicated and expensive. They require relatively large blood samples, which must be processed to serum or plasma before isolation of biomarkers can proceed. Such cumbersome sample preparation also limits the widespread use of powerful, downstream genomic analyses, including PCR and DNA sequencing. These limitations also preclude rapid, point-of-care diagnostic applications. Thus, new technologies that allow rapid isolation of biomarkers directly from blood will permit seamless sample-to-answer solutions that enable next-generation point-of-care molecular diagnostics.
KW - biomarkers
KW - cancer
KW - cell-free DNA
KW - cell-free RNA
KW - exosomes
KW - liquid biopsy
KW - molecular diagnostics
KW - nanoparticulates
KW - point-of-care
KW - sample preparation
UR - http://www.scopus.com/inward/record.url?scp=84940564438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940564438&partnerID=8YFLogxK
U2 - 10.1586/14737159.2015.1069709
DO - 10.1586/14737159.2015.1069709
M3 - Review article
C2 - 26189641
AN - SCOPUS:84940564438
VL - 15
SP - 1187
EP - 1200
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 9
ER -